Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Stockholders' Equity

v3.8.0.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Timeline Labs [Member]
DCC Labs [Member]
Common Stock [Member]
Common Stock [Member]
Timeline Labs [Member]
Common Stock [Member]
DCC Labs [Member]
Additional Paid-In Capital [Member]
Additional Paid-In Capital [Member]
Timeline Labs [Member]
Additional Paid-In Capital [Member]
DCC Labs [Member]
Accumulated Deficit [Member]
Cumulative Translation Adjustment [Member]
Unrealized Gain/Loss on Investments [Member]
Treasury Stock [Member]
Beginning balance at Jan. 31, 2015 $ 171,051     $ 327     $ 219,651     $ (43,172) $ (5,797) $ 43 $ (1)
Beginning balance, Shares at Jan. 31, 2015       32,733,636                 (39,784)
Issuance of common stock pursuant to exercise of stock options $ 193           193            
Issuance of common stock pursuant to exercise of stock options, Shares 28,740     28,740                  
Issuance of common stock pursuant to vesting of restricted stock units       $ 3     (3)            
Issuance of common stock pursuant to vesting of restricted stock units, Shares       278,544                  
Issuance of common stock pursuant to the acquisition   $ 4,779     $ 8     $ 4,771          
Issuance of common stock pursuant to the acquisition, Shares         777,857                
Purchase of treasury shares $ (1)                       $ (1)
Purchase of treasury shares, Shares                         (122)
Stock-based compensation expense 3,552           3,552            
Change in fair value on marketable securities (12)                     (12)  
Translation adjustment (847)                   (847)    
Net income (loss) (47,697)                 (47,697)      
Ending balance at Jan. 31, 2016 $ 131,018     $ 338     228,164     (90,869) (6,644) 31 $ (2)
Ending balance, Shares at Jan. 31, 2016       33,818,777                 (39,906)
Issuance of common stock pursuant to exercise of stock options, Shares 0                        
Issuance of common stock pursuant to vesting of restricted stock units $ 2     $ 2                  
Issuance of common stock pursuant to vesting of restricted stock units, Shares       208,474                  
Issuance of common stock pursuant to the acquisition   $ 3,203 $ 2,640   $ 5 $ 7   $ 3,198 $ 2,633        
Issuance of common stock pursuant to the acquisition, Shares         542,274 681,278              
Issuance of common stock pursuant to TLL purchase adjustment mechanism 249     $ 1     248            
Issuance of common stock pursuant to TLL purchase adjustment mechanism, Shares       70,473                  
Issuance of common stock pursuant to ESPP purchases 61           61            
Issuance of common stock pursuant to ESPP purchases, Shares       17,956                  
Purchase of treasury shares (3)                       $ (3)
Purchase of treasury shares, Shares                         (584)
Stock-based compensation expense 2,621           2,621            
Fiscal 2016 compensation paid in restricted stock units (248)           (248)            
Change in fair value on marketable securities (25)                     (25)  
Translation adjustment 1,267                   1,267    
Net income (loss) (71,249)                 (71,249)      
Ending balance at Jan. 31, 2017 $ 69,536     $ 353     236,677     (162,118) (5,377) 6 $ (5)
Ending balance, Shares at Jan. 31, 2017       35,339,232                 (40,490)
Issuance of common stock pursuant to exercise of stock options, Shares 0                        
Issuance of common stock pursuant to vesting of restricted stock units       $ 3     (3)            
Issuance of common stock pursuant to vesting of restricted stock units, Shares       271,285                  
Issuance of common stock pursuant to ESPP purchases $ 53           53            
Issuance of common stock pursuant to ESPP purchases, Shares       24,467                  
Stock-based compensation expense 2,696           2,696            
Change in fair value on marketable securities (60)                     (60)  
Translation adjustment (3)                   (3)    
Net income (loss) 13,498                 13,498      
Ending balance at Jan. 31, 2018 $ 85,720     $ 356     $ 239,423     $ (148,620) $ (5,380) $ (54) $ (5)
Ending balance, Shares at Jan. 31, 2018       35,634,984                 (40,490)